Synlico Inc. envisions rewriting medicine by bringing causality to cellular biology. As an AI-powered drug discovery biotech company, our primary mission is to develop cutting-edge engineered T cell therapies to combat solid tumors. Harnessing advancements in single-cell bioinformatics, machine learning, and causal discovery, our team is developing a computational platform that provides a granular description of the heterogeneity of the tumor microenvironment (TME) and reclassifies patients by their unique TME signatures. Our platform will enable us to design potent T cell therapies by discovering the causal relationship between intracellular elements of T cells and their behaviors in patients' TME, surmounting the challenges presented by the complex nature of solid tumors and their microenvironments.